Novartis's Entresto Doesn't Impress In 1Q; Orphan Drug Fails In PhIII

Novartis AG's newly launched heart failure drug Entresto (valsartan/sacubitril), which has been dubbed the company's next blockbuster product, missed the mark in the first quarter of the year, posting sales more than $10m below analyst forecasts.